Results 21 to 30 of about 4,766 (189)

Pharmacokinetic drug interactions of integrase strand transfer inhibitors

Current Research in Pharmacology and Drug Discovery, 2021
The integrase strand transfer inhibitor (INSTI)-containing regimens are currently considered as the first-line treatment of human immunodeficiency virus (HIV) infection.
Chi-Hua Lu, Edward M. Bednarczyk, Linda M. Catanzaro, Alyssa Shon, Jia-Chen Xu, Qing Ma   +5 more
doaj   +1 more source

Elvitegravir: A New HIV Integrase Inhibitor [PDF]

Antiviral Chemistry and Chemotherapy, 2009
Integration is a distinctive and essential process in the HIV infection cycle and thus represents an attractive antiviral drug target. Integrase inhibitors combined with other classes of drug might contribute to long-lasting suppression of HIV type-1 (HIV-1) replication for many patients.
Kazuya, Shimura, Eiichi N, Kodama
openaire   +2 more sources

Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting

Antiviral Therapy, 2023
Background Cohort studies suggest higher discontinuation rates with integrase strand transfer inhibitors (INSTIs) than are seen in clinical trials. We assessed discontinuations and adverse events (AEs) that were considered related to the initial INSTI in
Charlotte-Paige Rolle MD, MPH, Jamie Castano, Vu Nguyen MS, Kiran Patel, Federico Hinestrosa MD, Edwin DeJesus MD   +5 more
doaj   +1 more source

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors

Frontiers in Microbiology, 2019
More than 10 million people worldwide are infected with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to severe adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy ...
Michał S. Barski, Jordan J. Minnell, Goedele N. Maertens   +2 more
doaj   +1 more source

A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir

Molecular Brain, 2020
Glutamate toxicity is a pathomechanism that contributes to neuronal cell death in a wide range of acute and chronic neurodegenerative and neuroinflammatory diseases.
Simon F. Merz, C. Peter Bengtson, Clara Tepohl, Anna M. Hagenston, Hilmar Bading, Carlos Bas-Orth   +5 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study

, 2020
Contains fulltext : 229127.pdf (Publisher’s version ) (Open Access)This phase-IV study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 HIV-1-positive women.
Bukkems, V.E., Burger, D.M., Garcia, C., Konopnicki, D., Schwarze-Zander, C., Lambert, J.S., Necsoi, C., Tenorio, C.H., Rockstroh, J., Colbers, A.   +9 more
core   +2 more sources

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals [PDF]

, 2021
Objectives Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and ...
Decosterd, Laurent A., Keiser, O., Stöckle, M., Aouri, Manel, Martinez de Tejada, B., Hösli, I., Marzolini, C., Haerry, D., Battegay, M., Vernazza, P., Rudin, C., Kahlert, C., Böni, J., Kovari, H., Nadal, D., Weber, R., Kouyos, R., Regenass, S., Dollenmaier, G., Egger, M., Schmid, P., Günthard, H., Martinetti, G., Guidi, Monia, Bucher, HC, Hasse, B., Yerly, S., Braun, DL, Gaspar, Frédéric, Barceló, Catalina, Nicca, D., Burton-Jeangros, C., Buclin, Thierry, Bernasconi, E., Calmy, A., Trkola, A., Cavassini, M., Kaiser, L., Aubert, V., Elzi, L., Gorgievski, M., Hirsch, HH, Csajka, Chantal, Rotger, Margalida, Fellay, J., Panchaud, Alice, Müller, N., Rauch, A., Ledergerber, B., Tarr, P., Pantaleo, G., Metzner, K., Furrer, H., Hoffmann, M., Fux, CA, Speck, R., Klimkait, T., Fehr, J., Cavassini, Matthias, Schöni-Affolter, F.   +59 more
core  

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

European Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice, 2019
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian ...
Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky   +17 more
doaj   +1 more source